Sökning: WFRF:(Sjölund Kristina) > Anti-tumor effects ...
Fältnamn | Indikatorer | Metadata |
---|---|---|
000 | 06657naa a2200457 4500 | |
001 | oai:lup.lub.lu.se:82a74a74-571a-4a77-96e2-33b2e80f4ba1 | |
003 | SwePub | |
008 | 210706s2021 | |||||||||||000 ||eng| | |
024 | 7 | a https://lup.lub.lu.se/record/82a74a74-571a-4a77-96e2-33b2e80f4ba12 URI |
024 | 7 | a https://doi.org/10.1016/j.tranon.2021.1011492 DOI |
040 | a (SwePub)lu | |
041 | a engb eng | |
042 | 9 SwePub | |
072 | 7 | a art2 swepub-publicationtype |
072 | 7 | a ref2 swepub-contenttype |
100 | 1 | a Radke, Katarzynau Lund University,Lunds universitet,Avdelningen för translationell cancerforskning,Institutionen för laboratoriemedicin,Medicinska fakulteten,Molekylär barnonkologi,Forskargrupper vid Lunds universitet,LUCC: Lunds universitets cancercentrum,Övriga starka forskningsmiljöer,Division of Translational Cancer Research,Department of Laboratory Medicine,Faculty of Medicine,Molecular Pediatric Oncology,Lund University Research Groups,LUCC: Lund University Cancer Centre,Other Strong Research Environments4 aut0 (Swepub:lu)ka1400ra |
245 | 1 0 | a Anti-tumor effects of rigosertib in high-risk neuroblastoma |
264 | 1 | b Elsevier BV,c 2021 |
520 | a High-risk neuroblastoma has a poor prognosis despite intense treatment, demonstrating the need for new therapeutic strategies. Here we evaluated the effects of rigosertib (ON-01910.Na) in preclinical models of high-risk neuroblastoma. Among several hundred cancer cell lines representing 24 tumor types, neuroblastoma was the most sensitive to rigosertib. Treatment of MYCN-amplified neuroblastoma organoids resulted in organoid disintegration, decreased cell viability, and increased apoptotic cell death. Neuroblastoma response to rigosertib involved G2M cell cycle arrest and decreased phosphorylation of AKT (Ser473) and ERK1/2 (Thr202/Tyr204). Rigosertib delayed tumor growth and prolonged survival of mice carrying neuroblastoma MYCN-amplified PDX tumors (median survival: 31 days, treated; 22 days, vehicle) accompanied with increased apoptosis in treated tumors. We further identified vincristine and rigosertib as a potential promising drug combination treatment. Our results show that rigosertib might be a useful therapeutic agent for MYCN-amplified neuroblastomas, especially in combination with existing agents. | |
650 | 7 | a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Cancer och onkologi0 (SwePub)302032 hsv//swe |
650 | 7 | a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Cancer and Oncology0 (SwePub)302032 hsv//eng |
653 | a Neuroblastoma | |
653 | a ON-01910 | |
653 | a ON-01910.Na | |
653 | a Patient-derived xenografts | |
653 | a Rigosertib | |
700 | 1 | a Hansson, Karinu Lund University,Lunds universitet,Avdelningen för translationell cancerforskning,Institutionen för laboratoriemedicin,Medicinska fakulteten,Molekylär barnonkologi,Forskargrupper vid Lunds universitet,Division of Translational Cancer Research,Department of Laboratory Medicine,Faculty of Medicine,Molecular Pediatric Oncology,Lund University Research Groups4 aut0 (Swepub:lu)med-knh |
700 | 1 | a Sjölund, Jonasu Lund University,Lunds universitet,Avdelningen för translationell cancerforskning,Institutionen för laboratoriemedicin,Medicinska fakulteten,Experimentell onkologi,Forskargrupper vid Lunds universitet,Division of Translational Cancer Research,Department of Laboratory Medicine,Faculty of Medicine,Experimental oncology,Lund University Research Groups4 aut0 (Swepub:lu)molm-sjo |
700 | 1 | a Wolska, Magdalenau Lund University4 aut |
700 | 1 | a Karlsson, Jennyu Lund University,Lunds universitet,Avdelningen för klinisk genetik,Institutionen för laboratoriemedicin,Medicinska fakulteten,Cancercellers evolution,Forskargrupper vid Lunds universitet,LUCC: Lunds universitets cancercentrum,Övriga starka forskningsmiljöer,Division of Clinical Genetics,Department of Laboratory Medicine,Faculty of Medicine,Pathways of cancer cell evolution,Lund University Research Groups,LUCC: Lund University Cancer Centre,Other Strong Research Environments4 aut0 (Swepub:lu)molm-jka |
700 | 1 | a Esfandyari, Javanshiru Lund University,Lunds universitet,Avdelningen för translationell cancerforskning,Institutionen för laboratoriemedicin,Medicinska fakulteten,Molekylär barnonkologi,Forskargrupper vid Lunds universitet,Division of Translational Cancer Research,Department of Laboratory Medicine,Faculty of Medicine,Molecular Pediatric Oncology,Lund University Research Groups4 aut0 (Swepub:lu)med-jie |
700 | 1 | a Pietras, Kristianu Lund University,Lunds universitet,Avdelningen för translationell cancerforskning,Institutionen för laboratoriemedicin,Medicinska fakulteten,Experimentell onkologi,Forskargrupper vid Lunds universitet,Division of Translational Cancer Research,Department of Laboratory Medicine,Faculty of Medicine,Experimental oncology,Lund University Research Groups4 aut0 (Swepub:lu)med-kpi |
700 | 1 | a Aaltonen, Kristinau Lund University,Lunds universitet,Avdelningen för translationell cancerforskning,Institutionen för laboratoriemedicin,Medicinska fakulteten,Molekylär barnonkologi,Forskargrupper vid Lunds universitet,Division of Translational Cancer Research,Department of Laboratory Medicine,Faculty of Medicine,Molecular Pediatric Oncology,Lund University Research Groups4 aut0 (Swepub:lu)cob-ked |
700 | 1 | a Gisselsson, Davidu Lund University,Lunds universitet,Avdelningen för klinisk genetik,Institutionen för laboratoriemedicin,Medicinska fakulteten,Cancercellers evolution,Forskargrupper vid Lunds universitet,Division of Clinical Genetics,Department of Laboratory Medicine,Faculty of Medicine,Pathways of cancer cell evolution,Lund University Research Groups,Skåne University Hospital4 aut0 (Swepub:lu)kgen-dgi |
700 | 1 | a Bexell, Danielu Lund University,Lunds universitet,Avdelningen för translationell cancerforskning,Institutionen för laboratoriemedicin,Medicinska fakulteten,Molekylär barnonkologi,Forskargrupper vid Lunds universitet,Division of Translational Cancer Research,Department of Laboratory Medicine,Faculty of Medicine,Molecular Pediatric Oncology,Lund University Research Groups4 aut0 (Swepub:lu)stem-dbe |
710 | 2 | a Avdelningen för translationell cancerforskningb Institutionen för laboratoriemedicin4 org |
773 | 0 | t Translational Oncologyd : Elsevier BVg 14:8q 14:8x 1936-5233 |
856 | 4 | u http://dx.doi.org/10.1016/j.tranon.2021.101149x freey FULLTEXT |
856 | 4 | u https://doi.org/10.1016/j.tranon.2021.101149 |
856 | 4 8 | u https://lup.lub.lu.se/record/82a74a74-571a-4a77-96e2-33b2e80f4ba1 |
856 | 4 8 | u https://doi.org/10.1016/j.tranon.2021.101149 |
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.